Chris Ullman

Point Richmond Tech Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Yann Jouvenot

Bio-Rad (United States)

Katherine Howes

Lawrence Berkeley National Laboratory

Andrew R. McNamara

Roche (Switzerland)

Lindsey Reynolds

University of Louisville

Mark Isalan

Imperial College London

Bradley Campos

Sangamo BioSciences (United States)

Michael J. Moore

Toronto Metropolitan University

Albert Lai

University of California, Los Angeles

S. Kaye Spratt

Abeona Therapeutics (United States)

Albert R. Davalos

Buck Institute for Research on Aging

Cooperative Institutions

Sangamo BioSciences (United States)

Point Richmond Tech Center

Lawrence Berkeley National Laboratory

European Molecular Biology Laboratory

Harvard University

Centre National de la Recherche Scientifique

Medical Research Council

Imperial College London

Peking University

MRC Laboratory of Molecular Biology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity

Proceedings of the National Academy of Sciences (2003)

Siyuan Tan Dmitry Guschin Albert R. Davalos Ya-Li Lee Andrew Snowden

Zinc-finger protein transcription factors (ZFP TFs) can be designed to control the expression of any desired target gene, and thus provide potential therapeutic tools for the study and treatment of disease. Here we report that a ZFP TF can repress target gene expression with single-gene specificity within the human genome. A ZFP TF repressor that binds an 18-bp recognition sequence within the promoter of the endogenous CHK2 gene gives a >10-fold reduction in CHK2 mRNA and protein. This level of repression was sufficient to generate a functional phenotype, as demonstrated by the loss of DNA damage-induced CHK2-dependent p53 phosphorylation. We determined the specificity of repression by using DNA microarrays and found that the ZFP TF repressed a single gene ( CHK2 ) within the monitored genome in two different cell types. These data demonstrate the utility of ZFP TFs as precise tools for target validation, and highlight their potential as clinical therapeutics.

10.1073/pnas.2035056100

Cite

Citations (150)